Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced that it has received marketing approvals from South Korean regulatory authorities for three of its cardiovascular products: the HT Supreme drug-eluting stent, the NC ROCKSTAR non-compliant balloon dilation catheter, and the SC HONKYTONK coronary balloon dilation catheter.
The HT Supreme drug-eluting stent is a drug-device combination used for improving the coronary artery lumen diameter in patients with symptomatic heart disease caused by primary coronary artery lesions up to 31 millimeters in length, with a reference vessel diameter of 2.25 to 3.50 millimeters. This approval marks an important step for Sino Medical Sciences as it expands its footprint in the global cardiovascular device market.
The NC ROCKSTAR non-compliant balloon dilation catheter is designed for balloon dilation of autologous coronary artery or bypass stenosis to enhance myocardial perfusion in patients with atherosclerosis. The SC HONKYTONK coronary artery balloon dilation catheter is a rapid exchange (Rx type) catheter used to dilate narrowed segments of coronary arteries or narrowed areas of bypass grafts, further improving myocardial perfusion.
These approvals reflect Sino Medical Sciences Technology Inc.’s commitment to innovation and quality, offering South Korean patients and medical professionals advanced solutions for the treatment of cardiovascular diseases.- Flcube.com
